Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Study (n=8,910) confirmed previous observations that underlying cardiovascular disease is associated with an increased risk of mortality among patients hospitalised with Covid-19. However, a potential harmful association of ACE inhibitors or ARBs with mortality was not observed.

SPS commentary:

An accompanying editorial discusses the implications of this study and two other related studies, noting that whilst all studies are observational studies with the potential for confounding, none of them demonstrated evidence of harm with continued use of ACE inhibitors and ARBs.


New England Journal of Medicine

Resource links:


Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19